A5025732778- Autoimmune Bullous Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Drug-Induced Adverse Reactions
- Oral and gingival health research
- Autoimmune and Inflammatory Disorders
- Urticaria and Related Conditions
- Allergic Rhinitis and Sensitization
- Platelet Disorders and Treatments
- Cytomegalovirus and herpesvirus research
- Dermatology and Skin Diseases
- Acne and Rosacea Treatments and Effects
- Testicular diseases and treatments
- Neutropenia and Cancer Infections
- Nail Diseases and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Biomedical Research and Pathophysiology
- Vitamin C and Antioxidants Research
- Asthma and respiratory diseases
- Chronic Lymphocytic Leukemia Research
- Medical Imaging and Pathology Studies
- Infections and bacterial resistance
- Infectious Diseases and Tuberculosis
- Eosinophilic Disorders and Syndromes
- Neonatal Respiratory Health Research
- Actinomycetales infections and treatment
Kawasaki Medical School
2019-2025
Tokushima University
2016-2023
Kanto Central Hospital
2001
Abstract The concept of immune reconstitution inflammatory syndrome (IRIS) has recently been applied to patients with non‐HIV infection fluctuations. However, quantitative criteria diagnose IRIS have not established. Similarly, immune‐related adverse events (irAEs) caused by checkpoint inhibitors (ICIs) are also No study directly compared the immunological indicators and irAEs. Thus, we investigated whether irAEs can be included in IRIS. We aimed search for diagnostic biomarkers compare...
Abstract Programmed death 1 (PD‐1) inhibitors are increasingly used for the treatment of malignancies. Despite clinical benefits, unpredictable and potentially fatal side‐effects may occur. We report a psoriatic patient who developed systemic capillary leak syndrome (SCLS) after starting PD‐1 checkpoint inhibitor. In order to determine which factors could trigger development SCLS in with stable psoriasis anti‐PD‐1 therapy, serum cytokines were serially measured before this patient. also...
Abstract Many cases of bullous pemphigoid (BP) have been reported in patients taking dipeptidyl peptidase‐4 inhibitors (DPP‐4i), which are the most widely used antidiabetic drug for type 2 diabetes mellitus. However, no large‐scale survey has conducted Japan. This retrospective study investigated incidence, clinical presentation, and course DPP‐4i‐associated BP (DPP‐4i‐BP) using epidemiological data from a nationwide registry BP. In 2016, 713 new at 94 dermatological institutes were...
Bullous pemphigoid (BP) is a rare autoimmune blistering disease, and the prevalence of type 2 diabetes mellitus (T2DM) relatively high in subjects with BP. It known that dipeptidyl peptidase-4 inhibitor (DPP-4i), one kind antidiabetic drugs, can cause BP, although precise mechanism DPP-4i-related BP remains unclear. In this report, we showed case appearance various disease-specific antibodies after onset Furthermore, became positive titers two years discontinuation DPP-4i. These data it...
Abstract Background The prognosis of dipeptidyl peptidase‐4 inhibitor‐associated bullous pemphigoid (DPP‐4i‐BP) is variable, with some cases showing spontaneous remission after drug cessation and others worsening BP or developing infectious complications, termed immune reconstitution inflammatory syndrome (IRIS), DPP‐4i cessation. We recently demonstrated that the neutrophil‐to‐lymphocyte ratio measured at baseline during treatment predicts eventual development IRIS. Objectives To identify...
症例は75歳女性. 1991年4月 (69歳) より心肥大, 慢性肝炎, 慢性腎不全などにて当院へ通院開始. 1992年末, 右上腕に皮下結節出現. 1993年6月, 血液透析導入に至ったが, 右上腕皮膚の疼痛, 皮下石灰化に伴う変形, 色素沈着, 潰瘍が出現し徐々に進行. 半年後に左上腕に皮下石灰化が出現. 1994年9月には洞不全をきたし, ペースメーカーが植え込まれた. 1995年, 両大腿前面皮下に小石灰化病変が出現. 1997年9月に腰痛などで入院した. 入院時所見で両側上腕皮下に塊状, 板状の石灰化 (tumoral calcinosis) が認められ, 右上腕皮膚に石灰化部分が露出した潰瘍がみられた. 潰瘍部の生検では真皮の小血管周囲に炎症細胞浸潤あり, 膠原線維の著明な増生がみられ, 数箇所に石灰化病変が認められたが, 脂肪織に炎症はみられなかった. 石灰化部分の分析ではリン酸カルシウム51%, 炭酸カルシウム49%であった. 血中intact PTH (i-PTH) は140pg/mlと高く, またCa 9.0mg/dl, P 8.5mg/dl (Ca×P...
Abstract Background Many reports have described the development of bullous pemphigoid (BP) following COVID‐19 vaccination. In dipeptidyl peptidase‐4 inhibitor‐associated BP (DPP‐4i‐BP), cessation DPP‐4i appears to a paradoxical effect on clinical course BP. Interestingly, similar reactions been shown develop after antibody‐based therapies that inhibit pro‐inflammatory cytokine signalling. These heterogenous outcomes could be explained by assuming DPP‐4i‐BP is manifestation immune...
黒色菌糸症は免疫不全患者の皮膚に好発する，黒色真菌による深在性真菌症である．今回，黒色菌糸症を2症例経験し，うち1症例で膿のKOH鏡検により迅速に診断を行えたので報告する．症例１は，87歳男性．肺小細胞癌(stageⅣB)に対して緩和治療中．初診の3か月前に転倒による外傷歴があり，抗菌薬による加療を受けたが，左環指基部腹側の発赤・腫脹が継続するため受診した．波動を触知し，超音波検査で皮下に境界明瞭な低エコー領域を認めた．膿汁の直接鏡検で多数の菌糸が観察された．症例2は，80歳男性．コントロール不良の2型糖尿病あり．1年前より右母指基部背側の小結節が出現，排膿を繰り返し，抗菌薬内服で改善しないため受診した．皮膚生検ではHE染色で両例とも肉芽腫性細胞浸潤を形成し，症例2では茶褐色調の菌糸を確認した．両例ともにGrocott染色で菌糸を多数認め，深在性皮膚真菌症と診断した．真菌培養及び遺伝子解析の結果から，症例1はPleurostomophora richardsiae，症例2はExophiala...